scholarly journals A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma

2020 ◽  
Author(s):  
Irene Tsung ◽  
Francis P. Worden ◽  
Robert J. Fontana
Keyword(s):  
Squamous Cell Carcinoma ◽  
Pilot Study ◽  
Cell Carcinoma ◽  
Checkpoint Inhibitors ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Solid Organ Transplant Recipients

Head and neck squamous cell carcinoma in solid organ transplant recipients

2020 ◽  
Author(s):  
Isabel Fernández-Carrera González ◽  
Christian Ibarra Estupiñan ◽  
Irene Rivero Fernández ◽  
Marta Sanz Rodríguez ◽  
Esther García González ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Neck Squamous Cell Carcinoma ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Solid Organ Transplant Recipients

Safety and efficacy of checkpoint inhibitors in solid organ transplant recipients with cutaneous squamous cell carcinoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e22014-e22014
Author(s):  
Irene Tsung ◽  
Francis P. Worden ◽  
Robert J. Fontana
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Response ◽  
Checkpoint Inhibitors ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Solid Organ ◽  
Safety And Efficacy ◽  
Allograft Function

e22014 Background: Immune checkpoint inhibitors (ICI) are increasingly used in solid organ malignancies. However, data are limited regarding their safety and efficacy in solid organ transplant (SOT) recipients at risk for allograft rejection. The aim of this study was to review our experience with ICIs in SOT recipients at a large transplant center. Methods: A retrospective review of ICIs used in SOT recipients from April 2011 to September 2019 was undertaken. Patient clinical and demographic features, ICI regimen, immunosuppression, allograft function, and efficacy were reviewed. Results: There were 8 SOT recipients (3 kidney, 4 liver, 1 lung) with 7 diagnosed with metastatic head and neck (H&N) cutaneous squamous cell carcinoma (cSCC) and 1 with Merkel cell carcinoma. At a median of 150 months [79-219] post-transplant, 6 were treated with cemiplimab and 2 with pembrolizumab after minimizing calcineurin inhibitors (CNI). Overall tumor response was 37.5% at a median of 3.8 months [0-8] of follow-up. However, 3 died of tumor progression and 2 of other causes at a median of 55 days [8-214] after starting ICI. The only irAE reported was severe pneumonitis in one patient requiring intubation and ICI discontinuation but responded to steroids. Two patients received prophylactic steroids and have preserved allograft function and ongoing tumor response at month 6. Conclusions: Our data suggest that minimization of CNI along with judicious use of prophylactic steroids may allow for the safe use of ICIs in SOT recipients with advanced H&N cSCC. Short-term efficacy appears promising and prospective studies are warranted. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document